Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today
Sanjeev Kumar | January 16, 2026 10:21 PM CST
The company said that enrollment for its randomized registrational QUILT-2.005 trial has surpassed internal expectations and is now more than 85% complete.
ImmunityBio, Inc. (IBRX) shares jumped 24% in premarket trading on Friday after the company reported a faster than expected enrollment for its QUILT-2.005 bladder cancer drug trial.
Add Asianet Newsable as a Preferred Source
The company said that enrollment has surpassed internal expectations and is now more than 85% complete, with full enrollment of the planned study population expected by the second quarter of 2026.
Based on current progress, ImmunityBio plans to submit a biologics license application to the U.S. Food and Drug Administration (FDA) by the end of 2026.
Read updates on this developing story on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
READ NEXT
-
Petrol drivers hit with 57p per litre charges
-
BJP Confident of First Marathi Mayor in Mumbai After Landslide Win in BMC Polls
-
'I'm a World Cup star and was ready to sign for Man Utd - then everything changed'
-
Postman says 'this doesn't make sense' after discovering bizarre road markings
-
'7 life-changing cleaning tips I learnt from my housekeeper that I still do'
